Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors

Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.79%. At the same time, the Dow added 0.26%, and the tech-heavy Nasdaq gained 1.52%. Shares of the drugmaker witnessed a loss of 4.92% over the previous month, trailing the performance of the Medical sector with its gain of 7.53%, and the S&P 500's loss of 1.82%.The upcoming earnings release of Pfizer will be of great interest to investors. The company's earnings report is expected on August 4, 2026. In that report, analysts expect Pfizer to post earnings of $0.68 per share. This would mark a year-over-year decline of 12.82%. In the meantime, our current consensus estimate forecasts the revenue to be $14.48 billion, indicating a 1.2% decline compared to the corresponding quarter of the prior year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.99 per share and a revenue of $61.85 billion, representing changes of -7.14% and -1.17%, respectively, from the prior year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Pfizer is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 8.16 right now. This denotes a discount relative to the industry average Forward P/E of 15.99. The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 89, finds itself in the top 37% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks